Jarrod Henshaw joins Prime Therapeutics as senior vice president, chief supply chain and industry relations officer
Henshaw will set the vision and provide strategic oversight for trade relations with pharmaceutical manufacturers, network management, pharmacy audit, and fraud, waste and abuse (FWA)
April 22, 2019
In this new role, Henshaw will set the vision and provide strategic oversight for trade relations with pharmaceutical manufacturers, network management, pharmacy audit, and fraud, waste and abuse (FWA). He will be a key contributor in advancing Prime’s growth, while assuring that Prime continues to deliver the highest quality and lowest cost of care to its clients and their members.
Henshaw comes to Prime from Healogics, a company providing health care services and technology solutions to hospitals and post-acute care facilities, based in Jacksonville, Fla. There he served in a number of roles, including chief innovation officer, executive vice president of supply chain, and chief legal officer. Prior to Healogics, he spent 14 years at Express Scripts (now Cigna) where he held roles such as chief strategy officer of supply chain and deputy general counsel.
“We are excited to welcome Jarrod to our leadership team,” said Chief Operating Officer Dave Overman of Prime. “He brings significant expertise in developing and executing supply chain strategies. His experience will help us maximize performance and create value for our clients and their members.”
Henshaw earned a Bachelor of Arts degree in Political Science from the University of Illinois at Urbana-Champaign, Illinois, and a Doctorate of Law from Saint Louis University in St. Louis, Missouri.
October 19, 2021
Going beyond the first fill: Prime Therapeutics, NCODA collaboration enables improved patient outcomes through new oncology pharmacy accreditation
EAGAN, Minn. and CAZENOVIA, NY – Prime Therapeutics (Prime), a leading pharmacy benefit…
October 18, 2021
Cancer patients, caregivers benefit with integrated clinic-to-pharmacy care through Prime Therapeutics’ IntegratedRx™ – Oncology
EAGAN, Minn. – Prime Therapeutics, a leading pharmacy benefit manager (PBM) serving more…
October 14, 2021
In first of its kind study, Prime Therapeutics explores paroxysmal nocturnal hemoglobinuria (PNH) C5 inhibitor treatment rates
EAGAN, Minn. – Leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) used its…